View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 5, 2019updated 12 Jul 2022 11:59am

Rexgenero opens enrolment for SALAMANDER trials in UK

Rexgenero has opened the first site in the UK to enrol diabetic patients with chronic limb-threatening ischemia (CLI) for the Phase III SALAMANDER studies of REX-001.

Rexgenero has opened the first site in the UK to enrol diabetic patients with chronic limb-threatening ischemia (CLI) for the Phase III SALAMANDER studies of REX-001.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The site at the University Hospital of Wales is participating via the Midlands-Wales Advanced Therapy Treatment Centre (MW-ATTC) consortium, which is part of the Advanced Therapy Treatment Centre Network (ATTC).

In alliance with the Cardiff & Vale University health board, the MW-ATTC intends to advance the SALAMANDER trials and activate new sites in the country.

REX-001 is an autologous regenerative cell therapy made with the patient’s bone marrow. It comprises immune cells and progenitor cells associated with immune modulation and tissue regeneration.

The therapy is given as a single dose within four days of the collection of bone marrow cells.

In a previous Phase II trial, a single REX-001 dose led to the healing of ischemic ulcers in 82% of patients within the initial 12 months.

The SALAMANDER trials will recruit a total of 60 patients suffering from CLI and rest pain and 78 CLI patients with non-healing ischemic ulcers at 25 hospitals across Europe.

Apart from the UK, the company will enrol patients in the Netherlands, Austria, Poland, Hungary, Czech Republic, Spain and Portugal.

Rexgenero CEO Joe Dupere said: “Treating our first patient with REX-001 in the UK will be an important milestone for our Phase III programme in diabetic patients with chronic-limb threatening ischemia, a severe condition with high unmet need.

“With clinical trial sites and manufacturing bases now open across multiple countries in Europe, we are one step closer to completion of the Phase III studies and potential regulatory and market approval for an innovative and much-needed product.”

Results from the Phase III SALAMANDER studies are set to be available in 2021.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena